These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 11273061)

  • 1. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.
    Elliott PM; Gimeno Blanes JR; Mahon NG; Poloniecki JD; McKenna WJ
    Lancet; 2001 Feb; 357(9254):420-4. PubMed ID: 11273061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Gimeno JR; Tomé-Esteban M; Lofiego C; Hurtado J; Pantazis A; Mist B; Lambiase P; McKenna WJ; Elliott PM
    Eur Heart J; 2009 Nov; 30(21):2599-605. PubMed ID: 19689975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
    Elliott PM; Gimeno JR; Tomé MT; Shah J; Ward D; Thaman R; Mogensen J; McKenna WJ
    Eur Heart J; 2006 Aug; 27(16):1933-41. PubMed ID: 16754630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
    Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
    Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ
    J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
    Magnusson P; Gadler F; Liv P; Mörner S
    Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients.
    El-Saiedi SA; Seliem ZS; Esmail RI
    Cardiol Young; 2014 Aug; 24(4):702-8. PubMed ID: 23895893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
    Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW
    J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
    J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.
    Spirito P; Bellone P; Harris KM; Bernabo P; Bruzzi P; Maron BJ
    N Engl J Med; 2000 Jun; 342(24):1778-85. PubMed ID: 10853000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.